美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Levonorgestrel	Intrauterine Device			Develop a method to characterize in vitro release			2014/02/14
Levonorgestrel	Tablet	II (Paddle)	75	0.1 N HCl with 0.1% SLS	1000	10, 20, 30, 45, 60 and 90	2004/02/05
Levorphanol Tartrate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2021/04/22
Levothyroxine Sodium	Tablet			Refer to USP			2007/07/25
Lidocaine	Topical Patch	Paddle over Disk (Apparatus 5)	50	Acetic acid/sodium acetate buffer, pH 4.0 at 32ºC	500	10, 20, 30, 60, 120 and 180	2007/01/03
Linaclotide	Capsule	I (Basket)	50	50 mM Phosphate Buffer, pH 4.5	500	5, 10, 15, 20 and 30	2015/12/24
Linagliptin	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Linagliptin/Metformin HCl	Tablet (Extended Release)	I (Basket)	100	Simulated Gastric Fluid (SGF) without enzyme (pH 1.2) (degassed)	900	Linagliptin 10, 15, 20, 30 and 45 minutes; Metformin: 1, 2, 4, 6, 8 and 12 hours	2016/07/28
Linagliptin/Metformin HCl	Tablet	II (Paddle)	50	0.1 N HCl	900	5, 10, 15, 20, 30 and 45	2014/05/15
Linezolid	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Linezolid	Suspension	II (Paddle)	50	0.05 M Phosphate Buffer, pH 6.8	900	10, 20, 30 and 45	2008/01/14
Liothyronine Sodium	Tablet			Refer to USP			2007/06/18
Lisdexamfetamine Dimesylate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Lisinopril	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Lithium Carbonate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Lithium Carbonate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Lithium Carbonate	Tablet (Extended Release)			Refer to USP			2008/01/14
Lomefloxacin HCl	Tablet	II (Paddle)	50	0.01 N HCl	900	10, 20, 30 and 45	2004/02/05
Lomitapide Mesylate	Capsule	II (Paddle)	50	0.001 N HCl with 0.1% Polysorbate 80	500 mL (5 mg strength); 1000 mL (10 and 20 mg strength)	5, 10, 20, 30 and 45	2015/06/25
Lomustine	Capsule			Develop a dissolution method			2015/12/24